Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Cowey, C., Lao, C., Wagstaff, J., Hogg, D., Hill, A., Carlino, M., Wolter, P., Lebbé, C., Schachter, J., Thomas, L., Hassel, J., Lorigan, P., Walker, D., Jiang, J., Hodi, F., & Wolchok, J. (n.d.). 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). European journal of cancer, 51, S664–S665. http://access.bl.uk/ark:/81055/vdc_100030687863.0x00003a